Dz042a

Manufactured by Merck Group

The DZ042A is a laboratory equipment product manufactured by Merck Group. It is a general-purpose device designed for use in various research and testing applications. The core function of the DZ042A is to perform specific tasks as required by the user, without further interpretation or extrapolation on its intended use.

Automatically generated - may contain errors

Lab products found in correlation

Mak044, by Merck Group (2 mentions) Mak266, by Merck Group (2 mentions) Mlb00c, by R&D Systems (2 mentions) Mak052, by Merck Group (2 mentions) Mak055, by Merck Group (2 mentions) Dy479 05, by R&D Systems (2 mentions) Mak043, by Abcam (2 mentions)

2 protocols using dz042a

Hepatic Biomarker Profiling in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Hepatic levels of TG (Sigma, MAK266), cholesterol (Sigma, MAK043), glycogen (Biovision, K646-100), total BA levels (Diazyme, DZ042A), serum NEFA (Sigma, MAK044), serum ALT (Sigma, MAK052), and serum AST (Sigma, MAK055) were determined according to the manufacturer’s instructions. Mouse liver IL-1β (R&D Systems, MLB00C) and CCL2 (R&D Systems, DY479-05) were detected by commercially available ELISA kit.

Chen J., Wang R., Xiong F., Sun H., Kemper B., Li W, & Kemper J. (2024). Hammerhead-type FXR agonists induce an enhancer RNA Fincor that ameliorates nonalcoholic steatohepatitis in mice. eLife, 13, RP91438.

+ Open protocol

+ Expand

Metabolic and Inflammatory Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Hepatic levels of TG (Sigma, MAK266), cholesterol (Sigma, MAK043), glycogen (Biovision, K646–100), total BA levels (Diazyme, DZ042A), serum NEFA (Sigma, MAK044), serum ALT (Sigma, MAK052) and serum AST (Sigma, MAK055) were determined according to the manufacturer’s instructions. Mouse liver IL-1β (R&D systems, MLB00C) and CCL2 (R&D systems, DY479–05) were detected by commercially available ELISA kit.

Chen J., Wang R., Xiong F., Sun H., Kemper B., Li W, & Kemper J.K. (2024). Hammerhead-type FXR agonists induce an eRNA FincoR that ameliorates nonalcoholic steatohepatitis in mice. bioRxiv.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!